A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer
Palo Alto (17 mi)Overseen byTe Vuong, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
No Placebo Group
Prior Safety Data
Approved in 4 jurisdictions
Trial Summary
What is the purpose of this trial?This trial is testing if starting chemotherapy earlier helps patients with operable rectal cancer stick to their treatment plan better. It targets patients who often struggle to complete their chemotherapy when it is given after other treatments. By splitting the chemotherapy into two parts, the study aims to make it easier for patients to finish their treatment.
Eligibility Criteria
Treatment Details
2Treatment groups
Experimental Treatment
Group I: Arm B - adjuvant chemotherapyExperimental Treatment2 Interventions
Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
Group II: A - neoadjuvant chemotherapyExperimental Treatment2 Interventions
Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
FOLFOX is already approved in United States, European Union, Japan, China for the following indications:
🇺🇸 Approved in United States as FOLFOX for:
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction adenocarcinoma
🇪🇺 Approved in European Union as FOLFOX for:
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction adenocarcinoma
🇯🇵 Approved in Japan as FOLFOX for:
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction adenocarcinoma
🇨🇳 Approved in China as FOLFOX for:
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction adenocarcinoma
Find a clinic near you
Research locations nearbySelect from list below to view details:
Hôpital de GatineauGatineau, Canada
Hôpital Charles LeMoyneGreenfield Park, Canada
Hôpital du SuroîtSalaberry-De-Valleyfield, Canada
Centre Hospitalier Pierre-BoucherLongueuil, Canada
More Trial Locations
Loading ...
Who is running the clinical trial?
Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
SanofiIndustry Sponsor